Dr. Weibo Luo is an Assistant Professor in the Departments of Pathology and Pharmacology at UT Southwestern Medical Center (UTSW) since December 2014. Dr. Luo received his Ph.D summa cum laude from the University of Magdeburg, Germany in 2007, completed his postdoctoral fellowship and instructorship with Dr. Gregg L. Semenza at the Johns Hopkins University School of Medicine before joining UTSW.
Dr. Luo studies oxygen homeostasis in tumor growth and metastasis at the molecular and cellular levels, with a particular focus on hypoxia-inducible factors (HIFs). He utilizes the multidisciplinary approaches to study crosstalk of HIF, epigenetics, and metabolism and their roles in tumor growth and metastasis. His overall goals are to identify the novel hypoxia-specific therapeutic targets and ultimately to translate knowledge to cancer therapy.
- Gene regulation
- Hypoxia-inducible factor
- Tumor growth and metastasis
- HIF repressors under chronic hypoxia.
- Luo W, Wang Y Aging (Albany NY) 2016 Mar
- PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia.
- Luo W, Chen I, Chen Y, Alkam D, Wang Y, Semenza GL Oncotarget 2016 Feb
- PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility.
- Luo W, Lin B, Wang Y, Zhong J, O'Meally R, Cole RN, Pandey A, Levchenko A, Semenza GL Mol. Biol. Cell 2014 Sep 25 18 2788-96
- Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
- Luo W, Chang R, Zhong J, Pandey A, Semenza GL Proc. Natl. Acad. Sci. U.S.A. 2012 Dec 109 49 E3367-76
- Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.
- Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL Cell 2011 May 145 5 732-44
- HIF-1a and TAZ serve as reciprocal co-activators in human breast cancer cells.
- Xiang L, Gilkes DM, Hu H, Luo W, Bullen JW, Liang H, Semenza GL Oncotarget 2015 May 6 14 11768-78
- Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype.
- Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL Oncotarget 2014 Dec 5 24 12509-27
- Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.
- Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF Clin. Cancer Res. 2014 Dec 20 24 6406-17
- Hypoxia-inducible factors enhance glutamate signaling in cancer cells.
- Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL Oncotarget 2014 Oct 5 19 8853-68
- Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis.
- Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, Chaturvedi P, Green JJ, Semenza GL Proc. Natl. Acad. Sci. U.S.A. 2014 Jun
Honors & Awards
- Susan G. Komen Career Catalyst Research Award
- Welch Foundation Research Award
- American Cancer Society (ACS-IRG) New Investigator Awards in Cancer Research
- CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (2014)
- AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Award
American Association for Cancer Research (2013)
- NIH Pathway to Independence Award
National Cancer Institute (2013)
- Albert L. Lehninger Postdoctoral Research Award
The Johns Hopkins University School of Medicine (2012)
- FARMS Postdoctoral Fellowship
Dr. Richard and Mavis Fowler Foundation for Advanced Research in the Medical Sciences, Inc (2011)
- PhD summa cum laude
University of Magdeburg, Germany (2007)
- American Association for Cancer Research (2011)